Bioregnum, Drug Development

BioRegnum snapshot: Who are the real insiders when it comes to healthcare policy?

 

Bioregnum
The view from Endpoints

If you want a brief glimpse at the root cause of the quagmire that healthcare policy represents in the US, check out Modern Healthcare’s list of the 100 most influential people in the industry.

Lists are always subjective displays of a publication’s inherent bias, and this one indicates that Modern Healthcare’s attitudes have been shaped almost entirely by the politicians, administration officials, lobbyists and a few provider group chiefs who populate the insiders club – found almost exclusively inside Washington D.C.’s beltway.

Steve Ubl, PhRMA President & CEO

Steve Ubl, PhRMA President & CEO

Aside from some key politicians, who professionally disagree on almost everything, payers and their lobbying organizations occupy the most important posts in this power game. Big BioPharma? A no show, except for PhRMA chief Steve Ubl. Drug developers? Just one, Patrick Soon-Shiong, who is found near the end. His billionaire status and photo ops rubbing shoulders with the DC crew likely played a role in that selection. If biopharma is truly virtually shut out of DC, as this list indicates, then look to payers and the next set of political power players in the post-election phase to determine your fate. That isn’t really the case, but it can’t be an appetizing thought.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017